KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
PE Stevens, SB Ahmed, JJ Carrero… - Kidney …, 2024 - kidney-international.org
This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
M Schechter, SD Wiviott, I Raz, EL Goodrich… - The Lancet Diabetes & …, 2023 - thelancet.com
Background In people with type 2 diabetes at high risk of cardiovascular or kidney disease,
sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of …
sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of …
Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials
RA Fletcher, N Jongs, GM Chertow… - Journal of the …, 2023 - journals.lww.com
Background Strategies to enable persistent use of renin–angiotensin system (RAS)
blockade to improve outcomes in CKD have long been sought. The effect of SGLT2 …
blockade to improve outcomes in CKD have long been sought. The effect of SGLT2 …
Dapagliflozin can alleviate renal fibrosis in rats with streptozotocin‑induced type 2 diabetes mellitus
S Xue, YX Li, XX Lu, W Tang - Experimental and …, 2023 - spandidos-publications.com
The aim of the present study was to explore the effects of Dapagliflozin on renal fibrosis in
streptozotocin (STZ)‑induced type 2 diabetes mellitus (T2DM) rats, and to determine the …
streptozotocin (STZ)‑induced type 2 diabetes mellitus (T2DM) rats, and to determine the …
The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy
H Hu, W Li, Y Hao, Z Peng, Z Zou, J Wei, Y Zhou… - Cell Reports …, 2024 - cell.com
Hyperuricemic nephropathy (HN) is a global metabolic disorder characterized by uric acid
(UA) metabolism dysfunction, resulting in hyperuricemia (HUA) and tubulointerstitial fibrosis …
(UA) metabolism dysfunction, resulting in hyperuricemia (HUA) and tubulointerstitial fibrosis …
Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of …
M Schechter, C Melzer Cohen, T Zelter… - Diabetes, Obesity …, 2023 - Wiley Online Library
2 METHODS The database includes over 2.2 million patients, and approximately 180 000
are in the diabetes registry, with a 99% yearly retention rate. Patients with T2D, who initiated …
are in the diabetes registry, with a 99% yearly retention rate. Patients with T2D, who initiated …
[HTML][HTML] Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial
SE Inzucchi, C Wanner, D Fitchett, B Zinman… - Diabetes Research and …, 2024 - Elsevier
Abstract In EMPA-REG OUTCOME, empagliflozin reduced the composite of total events
leading to/prolonging hospitalisation for any cause and all-cause mortality by 24% versus …
leading to/prolonging hospitalisation for any cause and all-cause mortality by 24% versus …
[HTML][HTML] 达格列净应用慢性肾脏病治疗研究进展
汪水发， 徐承云 - Advances in Clinical Medicine, 2024 - hanspub.org
目前, 慢性肾脏病已成为全球严峻的健康挑战, 其患病率和死亡率持续攀升. 在我国,
慢性肾脏病患者数量众多, 然而可用的治疗手段却相对有限. 近期研究指出, 达格列净不仅是一种 …
慢性肾脏病患者数量众多, 然而可用的治疗手段却相对有限. 近期研究指出, 达格列净不仅是一种 …
Dapagliflozin vermindert das Risiko für Krankenhausaufenthalte von Typ-2-Diabetes-Patienten
I Schamarek - Die Diabetologie, 2023 - Springer
Hintergrund. Patienten mit Typ-2-Diabetes haben ein höheres Risiko für die Notwendigkeit
von Krankenhausaufenthalten, was die Lebensqualität vermindert und Kosten erzeugt [1] …
von Krankenhausaufenthalten, was die Lebensqualität vermindert und Kosten erzeugt [1] …
达格列净对糖尿病肾病患者血管功能和肾功能的效果研究
常爱玲， 翟雅然， 王玉金， 张金成， 王方珍 - 实用临床医药杂志 - jcmp.yzu.edu.cn
《实用临床医药杂志》版权所有http://jcmp.yzu.edu.cn Page 1 《实用临床医药杂志》版权所有 http://jcmp.yzu.edu.cn
达格列净对糖'病肾病患者血管功能 和肾功能的效ж研究 !"#,$%&,'(),*)+,',- (河北省沧州市中心 …
达格列净对糖'病肾病患者血管功能 和肾功能的效ж研究 !"#,$%&,'(),*)+,',- (河北省沧州市中心 …